newsfilter
← Latest News
GlobeNewswire·

Merus Announces Financial Results for the Third Quarter 2024 and Provides Business Update

Phase 3 registrational trials evaluating petosemtamab in combination with pembrolizumab in 1L and petosemtamab monotherapy in 2/3L r/m HNSCC enrolling Petosemtamab in 2L+ r/m HNSCC interim clinical data accepted for